In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue 4 SUPPL. S1, 2000, Pages 13-21

  McCloskey, Lynn ^a   Moore, Terrance ^a   Niconovich, Nancy ^a   Donald, Brenda ^a   Broskey, John ^a   Jakielaszek, Charles ^a   Rittenhouse, Stephen ^a   Coleman, Ken ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; AZITHROMYCIN; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; GEMIFLOXACIN; GENTAMICIN; GREPAFLOXACIN; LEVOFLOXACIN; NALIDIXIC ACID; OFLOXACIN; PENICILLIN G; SULFAMETHOXAZOLE; TRIMETHOPRIM; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ACINETOBACTER; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ARTICLE; CITROBACTER FREUNDII; CONTROLLED STUDY; CULTURE MEDIUM; DILUTION; DRUG POTENCY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE TYPE A; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MORGANELLA MORGANII; NONHUMAN; PROTEUS; PSEUDOMONAS AERUGINOSA; SERRATIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS SAPROPHYTICUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PYOGENES; UNITED STATES;

ANTI-INFECTIVE AGENTS; BACTERIA; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES;

EID: 0034087347     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Kunin, C. M. (1997). Antibiotic armageddon. Clinical Infectious Diseases 25, 240-1.
2. Oh, J. I., Pak, K. S., Ahn, M. J., Kim, M. Y., Hong, C. Y., Kim, I. C. et al. (1996). In-vitro and in-vivo evaluations of LB20304, a new fluoronaphthyridone. Antimicrobial Agents and Chemotherapy 40, 1564-8.
3. Cormican, M. G. & Jones, R. N. (1997). Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone. Antimicrobial Agents and Chemotherapy 41, 204-11.
4. Sensititre Susceptibility System Technical Product Information. Non-Fastidious Procedure. AccuMed International Inc., Westlake, OH, USA.
5. National Committee for Clinical Laboratory Standards. (1999). Performance Standard for Antimicrobial Susceptibility Testing -Ninth Informational Supplement: Approved Standard M100-S9. NCCLS, Wayne, PA.
6. Craig, W. A. & Gudmundsson, S. (1986). The post antibiotic effect. In Antibiotics in Laboratory Medicine, 4th edn, (Lorian, V., Ed.), pp. 296-329. Williams & Wilkins, Baltimore, MD, USA.
7. Davies, T. A., Kelly, L. M., Pankuch, G. A., Credito, K. L., Jacobs, M. R. & Appelbaum, P. C. (2000). Antipneumococcal activity of gemifloxacin compared to those of nine other agents. Antimicrobial Agents and Chemotherapy 44, 304-10.
8. Davies, T., Kelly, L. M., Hoellman, D. B., Ednie, L. M., Clark, C. L., Bajaksouzian, S., Jacobs, M. R. & Appelbaum, P. C. (2000). Activities and postantibiotic effects of gemifloxacin compared to 11 other agents against Haemophilus influenzae and Moraxella catarrhalis. Antimicrobial Agents and Chemotherapy 44, 633-9.
9. Mackenzie, H., Forward, K., DeAzavedo, J., Low, D. E. & Davidson, R. J. (1999). Post-antibiotic effect (PAE) of gemifloxacin (SB-265805) in S. pneumoniae with diminished susceptibility to ciprofloxacin. In Program and Abstracts of the Thirty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 1501, p. 268. American Society for Microbiology, Washington, DC.